Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progenitor (PGEN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (37)	2/27/1998 2:40:00 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 106

Some updated information on PGEN: Corporate Profile for Progenitor, Inc., dated Feb. 27, 1998 Published Date: Feb. 27, 1998 Company Name: Progenitor, Inc. Address: 4040 Campbell Ave. Menlo Park, CA 94025 Main Telephone Number: 650/617-0880 Internet Home Page Address (URL): progenitor.com Chief Executive Officer: Douglass B. Given, M.D., Ph.D. Chief Financial Officer: Mark N.K. Bagnall Investor Relations Contact: Andrea Yamartino Business number: 650/614-7099 Home number: 650/328-5240 Public Relations Contact: Carrie B. Wick Business number: 650/614-7060 Home number: 614/436-3075 (based in Ohio currently) Trading Symbol/ Exchange: PGEN, PGENW Industry: Genomics/Biotech Market Makers: Lehman Brothers, Genesis Merchant Group, Herzog, Nash Weiss, Knight, Meyerson, Josephthal, Troster Singer, Neidiger Company description: Progenitor is engaged in the discovery and functional characterization of genes to identify targets for the development of new pharmaceuticals. The company's focus is on the identification of genes important in cancer, blood and immune system disorders and inherited diseases. Progenitor's genomics system focuses on understanding gene function in order to accelerate discovery of genes with medical relevance. The system combines core expertise in the fields of developmental biology, human disease genetics and bioinformatics, using developing cells and rigorously screened patient populations as unique discovery resources. The company's gene discoveries include B219, which encodes the leptin receptor; del-1, involved in blood vessel and bone formation; and HFE, responsible for hereditary hemochromatosis, an iron overload disease. Progenitor develops and commercializes its discoveries through partnerships with biopharmaceutical firms. The company has ongoing agreements with Amgen, SmithKline Beecham Clinical Laboratories, Novo Nordisk, Chiron, Pangea Systems, and Affymetrix. ------------------------------------------------------------------------ Contact: Progenitor, Inc.